Brought to you by 
Roche in ADC collaboration with Wilex’s Heidelberg Pharma; terminated
03 Feb 2023
Executive Summary
Heidelberg Pharma GMBH (conducts preclinical contract research and antibody-drug conjugate (ADC) development), a division of German cancer therapeutics and diagnostics company Wilex AG, has licensed Roche rights to its proprietary ADC technology, which the Big Pharma will apply to its own antibodies. Roche has options to develop and market resulting drugs.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche in ADC collaboration with Wilex’s Heidelberg Pharma; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice